BioLineRx | Clinical Trials

BioLineRx is currently supporting investigator-initiated clinical trials and research collaborations for the treatment of glioblastoma and pancreatic cancer. We encourage interested patients to speak with their healthcare team for more information on eligibility criteria for our active clinical trials.

Ongoing GLIX1 Clinical Trials

Study Locations

Glioblastoma

A map of the USA with pins indicating BioLine GLIX1 clinical trial sites.

STUDY TITLE

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

CLINICAL PARTNER

—

CONDITION

Glioblastoma

STUDY LOCATION

New York, NY
Tampa Bay, FL
Evanston, IL

PHASE

Phase 1/2a

INFORMATION

NCT07464925

Ongoing Motixafortide Clinical Trials

Study Locations

Investigator-initiated studies of motixafortide are currently enrolling patients in the following locations:

Pancreatic Cancer

STUDY TITLE

A Phase 2b Study with Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment-naïve Pancreas Adenocarcinoma

CLINICAL PARTNER

CONDITION

Pancreatic Cancer

STUDY LOCATION

New York, NY
Providence, RI
Milwaukee, WI
Boston, MA

PHASE

Phase 2b

INFORMATION

NCT04543071

Research Areas of Focus for Motixafortide

BioLineRx’s commitment to patients in need is supported not only through our own clinical studies, but also by supporting independent, unsolicited research relating to motixafortide by external investigators, organizations, and institutions as part of our Investigator Initiated Studies (IIS) program. IIS proposals submitted to BioLineRx are reviewed by our scientific and medical committees for scientific merit as well as safety, legal, ethical, and budgetary considerations. Support by BioLineRx can take the form of funding, study drug, or a combination of both.